RxDoctor Payments Data

Victoria Watson, MD

Family Medicine · Camden, TNNPI 1396373510

Payments from drug & device makers

$353in general payments, 2019–2025

Across 19 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$217
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$39
  • Novo Nordisk$20
  • Purdue Pharma L.p.$19
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$16
  • Supernus Pharmaceuticals, Inc.$15
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$353100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$353 in reported general payments places this provider in the 40th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$73,330
Medicare patients
188
Services billed
889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$44,671
JardianceEmpagliflozin33$34,706
JanuviaSitagliptin Phosphate15$19,823
EliquisApixaban17$17,042
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,221
TrulicityDulaglutide15$15,330
MounjaroTirzepatide14$13,205
FarxigaDapagliflozin Propanediol12$13,198
Spiriva RespimatTiotropium Bromide21$13,025
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,481
Atorvastatin Calcium119$1,425
Duloxetine Hcl73$1,372
Potassium Chloride38$1,105
Famotidine85$1,020
Gabapentin123$929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$20$44,67133 claims
Lilly USA, LLCTrulicity, Mounjaro$14$28,53529 claims
PfizerEliquis$14$17,04217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Camden

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →